Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study

Introduction: Ovarian cancer is a significant global health concern for women. More than 85-90% of ovarian cancer cases originates from epithelial causes. Dysfunctional p53 is a hallmark of many cancers, including ovarian cancer. Alteration in functioning of p53 gene has been connected to the onset...

Full description

Saved in:
Bibliographic Details
Main Authors: Geeta Bazard, Minakshi Vashist, Sunita Singh, Gulshan Rohilla, Nidhi Paliwal
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2024-12-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://www.jcdr.net/articles/PDF/20446/74248_CE[Ra1]_F(SL)_QC(SD_IS)_PF1(AG_SL)_redo_PFA(IS)_PB(AG_IS)_PN(IS).pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841560260363419648
author Geeta Bazard
Minakshi Vashist
Sunita Singh
Gulshan Rohilla
Nidhi Paliwal
author_facet Geeta Bazard
Minakshi Vashist
Sunita Singh
Gulshan Rohilla
Nidhi Paliwal
author_sort Geeta Bazard
collection DOAJ
description Introduction: Ovarian cancer is a significant global health concern for women. More than 85-90% of ovarian cancer cases originates from epithelial causes. Dysfunctional p53 is a hallmark of many cancers, including ovarian cancer. Alteration in functioning of p53 gene has been connected to the onset and spread of ovarian cancer. Aim: To analyse the Immunohistochemical (IHC) expression of p53 gene and clinicopathological features of Low-grade Serous Ovarian Cancer (LGSOC) and High-grade Serous Ovarian Cancer (HGSOC). Materials and Methods: This cohort study was conducted on 37 histopathologically confirmed cases of serous carcinomas of ovary in Department of Genetics, Maharshi Dayanand University, Rohtak, in collaboration with Department of Pathology, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India during the period 2019 to 2023. Study was approved by the Institutional Human Ethical Research Committee (Ref no-IHEC/19/07). Parameters of study included clinical features of ovarian cancer patients, histological types, the Federation of Gynaecology and Obstetrics stage, survival of patients and prognostic factors. Analysis of p53 expression was analysed immunohistochemically. Statistical analysis was performed using GraphPad PRISM Version 8.0.1. Results: A total of 37 cases of serous carcinoma were analysed, including 26 cases of HGSOC and 11 cases of LGSOC. Comparative analysis revealed advanced-stage disease in patients HGSOC, 20 cases (76.92%) compared to 4 cases (36.36%) in LGSOC. Additionally, higher median CA125 levels were found in HGSOC patients (median 269 U/mL vs. 27 U/mL) and a higher rate of postsurgery residual disease (57.69% vs. 27.27%). Among all serous carcinoma cases, 17 cases (45.95%) showed null p53 expression, 16 cases (43.24%) showed diffuse p53 expression, and four cases (10.81%) had focal positive expression (wild type). Statistically significant differences (p-value=0.02) between the grade of serous ovarian cancer and the expression of p53 were observed. However, median Overall Survival (OS) between the two groups (39 months for HGSOC vs. 41 months for LGSOC) showed a statistically non significant difference (p-value=0.51). Log-rank statistical analysis showed a non significant association between the overall survival time of the two grades, with a Hazard Ratio of 1.384 (0.5-3.5) at 95% confidence interval with p-value=0.51. Conclusion: The significant difference in p53 IHC expression between LGSOC and HGSOC highlighted the role of p53 mutation in pathogenesis of HGSOC. However, by understanding genetic predisposition of ovarian tumour preventive steps as well as planning of early treatment can reduce the mortality rate.
format Article
id doaj-art-3583eb53f97d4476a35ea88b10848cf9
institution Kabale University
issn 2249-782X
0973-709X
language English
publishDate 2024-12-01
publisher JCDR Research and Publications Private Limited
record_format Article
series Journal of Clinical and Diagnostic Research
spelling doaj-art-3583eb53f97d4476a35ea88b10848cf92025-01-04T12:18:27ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2024-12-011812101410.7860/JCDR/2024/74248.20446Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort StudyGeeta Bazard0Minakshi Vashist1Sunita Singh2Gulshan Rohilla3Nidhi Paliwal4PhD Student, Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana, India.Professor, Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana, India.Professor, Department of Pathology, Pandit Bhagwat Dayal University of Health Scienes, Rohtak, Haryana, India.PhD Student, Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana, India.PhD Student, Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana, India.Introduction: Ovarian cancer is a significant global health concern for women. More than 85-90% of ovarian cancer cases originates from epithelial causes. Dysfunctional p53 is a hallmark of many cancers, including ovarian cancer. Alteration in functioning of p53 gene has been connected to the onset and spread of ovarian cancer. Aim: To analyse the Immunohistochemical (IHC) expression of p53 gene and clinicopathological features of Low-grade Serous Ovarian Cancer (LGSOC) and High-grade Serous Ovarian Cancer (HGSOC). Materials and Methods: This cohort study was conducted on 37 histopathologically confirmed cases of serous carcinomas of ovary in Department of Genetics, Maharshi Dayanand University, Rohtak, in collaboration with Department of Pathology, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India during the period 2019 to 2023. Study was approved by the Institutional Human Ethical Research Committee (Ref no-IHEC/19/07). Parameters of study included clinical features of ovarian cancer patients, histological types, the Federation of Gynaecology and Obstetrics stage, survival of patients and prognostic factors. Analysis of p53 expression was analysed immunohistochemically. Statistical analysis was performed using GraphPad PRISM Version 8.0.1. Results: A total of 37 cases of serous carcinoma were analysed, including 26 cases of HGSOC and 11 cases of LGSOC. Comparative analysis revealed advanced-stage disease in patients HGSOC, 20 cases (76.92%) compared to 4 cases (36.36%) in LGSOC. Additionally, higher median CA125 levels were found in HGSOC patients (median 269 U/mL vs. 27 U/mL) and a higher rate of postsurgery residual disease (57.69% vs. 27.27%). Among all serous carcinoma cases, 17 cases (45.95%) showed null p53 expression, 16 cases (43.24%) showed diffuse p53 expression, and four cases (10.81%) had focal positive expression (wild type). Statistically significant differences (p-value=0.02) between the grade of serous ovarian cancer and the expression of p53 were observed. However, median Overall Survival (OS) between the two groups (39 months for HGSOC vs. 41 months for LGSOC) showed a statistically non significant difference (p-value=0.51). Log-rank statistical analysis showed a non significant association between the overall survival time of the two grades, with a Hazard Ratio of 1.384 (0.5-3.5) at 95% confidence interval with p-value=0.51. Conclusion: The significant difference in p53 IHC expression between LGSOC and HGSOC highlighted the role of p53 mutation in pathogenesis of HGSOC. However, by understanding genetic predisposition of ovarian tumour preventive steps as well as planning of early treatment can reduce the mortality rate.https://www.jcdr.net/articles/PDF/20446/74248_CE[Ra1]_F(SL)_QC(SD_IS)_PF1(AG_SL)_redo_PFA(IS)_PB(AG_IS)_PN(IS).pdfepithelialgenetic predispositionimmunohistochemistry
spellingShingle Geeta Bazard
Minakshi Vashist
Sunita Singh
Gulshan Rohilla
Nidhi Paliwal
Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
Journal of Clinical and Diagnostic Research
epithelial
genetic predisposition
immunohistochemistry
title Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
title_full Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
title_fullStr Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
title_full_unstemmed Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
title_short Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
title_sort immunohistochemical expression of p53 gene and clinicopathological assessment of low grade serous ovarian cancer and high grade serous ovarian cancer a cohort study
topic epithelial
genetic predisposition
immunohistochemistry
url https://www.jcdr.net/articles/PDF/20446/74248_CE[Ra1]_F(SL)_QC(SD_IS)_PF1(AG_SL)_redo_PFA(IS)_PB(AG_IS)_PN(IS).pdf
work_keys_str_mv AT geetabazard immunohistochemicalexpressionofp53geneandclinicopathologicalassessmentoflowgradeserousovariancancerandhighgradeserousovariancanceracohortstudy
AT minakshivashist immunohistochemicalexpressionofp53geneandclinicopathologicalassessmentoflowgradeserousovariancancerandhighgradeserousovariancanceracohortstudy
AT sunitasingh immunohistochemicalexpressionofp53geneandclinicopathologicalassessmentoflowgradeserousovariancancerandhighgradeserousovariancanceracohortstudy
AT gulshanrohilla immunohistochemicalexpressionofp53geneandclinicopathologicalassessmentoflowgradeserousovariancancerandhighgradeserousovariancanceracohortstudy
AT nidhipaliwal immunohistochemicalexpressionofp53geneandclinicopathologicalassessmentoflowgradeserousovariancancerandhighgradeserousovariancanceracohortstudy